These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


Pubmed for Handhelds

PUBMED FOR HANDHELDS

Journal Abstract Search

146 related items for PubMed ID: 12500046

  • 1.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 2. A formulation of aerosolized tobramycin (Bramitob) in the treatment of patients with cystic fibrosis and Pseudomonas aeruginosa infection: a double-blind, placebo-controlled, multicenter study.
    Chuchalin A, Csiszér E, Gyurkovics K, Bartnicka MT, Sands D, Kapranov N, Varoli G, Monici Preti PA, Mazurek H.
    Paediatr Drugs; 2007; 9 Suppl 1():21-31. PubMed ID: 17536872
    [Abstract] [Full Text] [Related]

  • 3.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 4. Effects of tobramycin solution for inhalation on global ratings of quality of life in patients with cystic fibrosis and Pseudomonas aeruginosa infection.
    Quittner AL, Buu A.
    Pediatr Pulmonol; 2002 Apr; 33(4):269-76. PubMed ID: 11921456
    [Abstract] [Full Text] [Related]

  • 5.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 6.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 7. Safety of inhaled (Tobi®) and intravenous tobramycin in young children with cystic fibrosis.
    Hennig S, McKay K, Vidmar S, O'Brien K, Stacey S, Cheney J, Wainwright CE.
    J Cyst Fibros; 2014 Jul; 13(4):428-34. PubMed ID: 24565869
    [Abstract] [Full Text] [Related]

  • 8.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 9.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 10. Novel tobramycin inhalation powder in cystic fibrosis subjects: pharmacokinetics and safety.
    Geller DE, Konstan MW, Smith J, Noonberg SB, Conrad C.
    Pediatr Pulmonol; 2007 Apr; 42(4):307-13. PubMed ID: 17352404
    [Abstract] [Full Text] [Related]

  • 11.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 12. Economic impact of tobramycin in patients with cystic fibrosis in a managed care population.
    Wertz DA, Chang CL, Stephenson JJ, Zhang J, Kuhn RJ.
    J Med Econ; 2011 Apr; 14(6):759-68. PubMed ID: 21942462
    [Abstract] [Full Text] [Related]

  • 13. Administration of aerosolized antibiotics in cystic fibrosis patients.
    Moss RB.
    Chest; 2001 Sep; 120(3 Suppl):107S-113S. PubMed ID: 11555564
    [Abstract] [Full Text] [Related]

  • 14.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 15. Intravenous versus oral antibiotics for eradication of Pseudomonas aeruginosa in cystic fibrosis (TORPEDO-CF): a randomised controlled trial.
    Hewer SCL, Smyth AR, Brown M, Jones AP, Hickey H, Kenna D, Ashby D, Thompson A, Williamson PR, TORPEDO-CF study group.
    Lancet Respir Med; 2020 Oct; 8(10):975-986. PubMed ID: 33007285
    [Abstract] [Full Text] [Related]

  • 16.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 17.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 18. Antimicrobial activity of tobramycin against respiratory cystic fibrosis Pseudomonas aeruginosa isolates from Bulgaria.
    Strateva T, Petrova G, Mitov I.
    J Chemother; 2010 Dec; 22(6):378-83. PubMed ID: 21303744
    [Abstract] [Full Text] [Related]

  • 19.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

  • 20.
    ; . PubMed ID:
    [No Abstract] [Full Text] [Related]

    Page: [Next] [New Search]
    of 8.